Positive. Sutro Biopharma's trial data on Luvelta in ovarian cancer shows promising results.

From Nasdaq, Inc.: 2025-03-16 21:49:25

Sutro Biopharma Inc. presented expanded data on luveltamab tazevibulin in platinum resistant ovarian cancer patients at the SGO Annual Meeting. The optimized dose of 5.2 mg/kg showed an ORR of 32% and a DCR of 96%, outperforming the 4.3 mg/kg group. Clinical activity was consistent across all levels of FRa expression, with an ORR of 30.8% and a DCR of 100% for PS 2+ =75%. Safety was maintained with no new signals, and neutropenia was well-managed. Most patients had prior bevacizumab treatment. For more health news, visit rttnews.com.



Read more at Nasdaq, Inc.: Sutro Biopharma :REFRaME-O1 Trial Data On Luvelta Shows Promise In Platinum-Resistant Ovarian Cancer